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A
 
BSTRACT
 
Background
 
Dual-chamber (atrioventricular) and
single-chamber (ventricular) pacing are alternative
treatment approaches for sinus-node dysfunction
that causes clinically significant bradycardia. However,
it is unknown which type of pacing results in the better
outcome.
 
Methods
 
We randomly assigned a total of 2010 pa-
tients with sinus-node dysfunction to dual-chamber
pacing (1014 patients) or ventricular pacing (996 pa-
tients) and followed them for a median of 33.1 months.
The primary end point was death from any cause or
nonfatal stroke. Secondary end points included the
composite of death, stroke, or hospitalization for heart
failure; atrial fibrillation; heart-failure score; the pace-
maker syndrome; and the quality of life.
 
Results
 
The incidence of the primary end point
did not differ significantly between the dual-chamber
group (21.5 percent) and the ventricular-paced group
(23.0 percent, P=0.48). In patients assigned to dual-
chamber pacing, the risk of atrial fibrillation was lower
(hazard ratio, 0.79; 95 percent confidence interval, 0.66
to 0.94; P=0.008), and heart-failure scores were better
(P<0.001). The differences in the rates of hospitaliza-
tion for heart failure and of death, stroke, or hospi-
talization for heart failure were not significant in un-
adjusted analyses but became marginally significant
in adjusted analyses. Dual-chamber pacing resulted
in a small but measurable increase in the quality of life,
as compared with ventricular pacing.
 
Conclusions
 
In sinus-node dysfunction, dual-cham-
ber pacing does not improve stroke-free survival, as
compared with ventricular pacing. However, dual-
chamber pacing reduces the risk of atrial fibrillation,
reduces signs and symptoms of heart failure, and
slightly improves the quality of life. Overall, dual-
chamber pacing offers significant improvement as
compared with ventricular pacing. (N Engl J Med
2002;346:1854-62.)
 
Copyright © 2002 Massachusetts Medical Society.
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INCE the first implantation of a cardiac pace-
maker in a human in 1958,
 
1
 
 technological ad-
vances have enhanced the sophistication of car-
diac pacemakers, but there has been no clear
evidence of the advantages of more complex devic-
es.
 
2-4
 
 For example, dual-chamber pacing maintains
atrioventricular synchrony and may better preserve
normal physiologic function as compared with single-
chamber ventricular pacemakers,
 
5-7
 
 but dual-chamber
pacemakers are more expensive, are more complex to
implant and program, and have a higher rate of com-
plications.
 
8
 
 Although retrospective studies and case se-
ries suggest benefits of dual-chamber or atrial-based
pacing,
 
9,10
 
 randomized trials have had divergent results
with regard to rates of death and stroke, particularly in
patients with sinus-node dysfunction.
 
11-14
 
 We investi-
gated whether dual-chamber pacing would provide
better event-free survival and quality of life than single-
chamber ventricular pacing in patients with sinus-node
dysfunction.
 
METHODS
 
The Mode Selection Trial in Sinus-Node Dysfunction (MOST)
was designed as a five-year trial to compare single-chamber (ven-
tricular), rate-modulated pacing with dual-chamber (atrioventric-
ular), rate-modulated pacing in patients whose sinus-node dysfunc-
tion required permanent pacing for bradycardia.
 
15
 
 The first patient
was enrolled on September 25, 1995, and the last patient on Octo-
S
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ber 13, 1999. Follow-up ended on January 31, 2001. The 2010
patients enrolled at 91 clinical sites had a median follow-up of 33.1
months.
 
Selection of Patients
 
Patients were eligible if they were at least 21 years old; were
undergoing initial implantation of a dual-chamber, rate modulated
pacing system for sinus-node dysfunction; and were in sinus rhythm
when randomly assigned to treatment. To be eligible for the quality-
of-life analyses, patients had to score 17 or higher on the Mini–
Mental State Examination
 
16
 
 before implantation. Patients with se-
rious concurrent illnesses, as determined by the investigator at each
site, were excluded.
 
Collection of Data before Implantation
 
Written informed consent was obtained before implantation.
Trained research coordinators collected base-line demographic, clin-
ical, and quality-of-life data. Coexisting conditions were assessed
with the Charlson comorbidity index.
 
17
 
 Multidimensional health-
related quality of life was assessed with the Medical Outcomes
Study 36-item Short-Form General Health Survey (SF-36).
 
18
 
 The
individual components of the SF-36 were used to calculate summary
scores for the physical and mental components.
 
19
 
 Cardiovascular
functional status was measured with the Specific Activity Scale.
 
20
 
Utilities were assessed with the time-tradeoff approach, in which
patients are asked a series of questions to determine how much
time in their present state of health they would trade for perfect
health.
 
21
 
Implantation, Randomization, Programming 
of Pacemakers, and Monitoring of Patients
 
After both atrial and ventricular leads were positioned, a 24-hour
randomization line was called, and the pacemaker was programmed
to the randomly assigned mode (rate-modulated dual-chamber
pacing or rate-modulated ventricular pacing) before implantation.
Patients were unaware of the pacing assignment. Randomization
was stratified according to the history of stroke and the clinical site.
For both assigned modes, the lower heart rate was programmed to
be at least 60 beats per minute, and the upper rate to be at least 110
beats per minute.
Follow-up evaluations occurred four times during the first year
and twice yearly thereafter. Quality-of-life assessments were per-
formed 3 and 12 months after enrollment and yearly thereafter,
with use of the SF-36 scales,
 
18,19
 
 the time-tradeoff utility score,
 
21
 
and the Specific Activity Scale class.
 
20
 
Primary and Secondary End Points
 
The primary end point was death from any cause or nonfatal
stroke. Prespecified secondary end points included the composite
of death from any cause, a first occurrence of stroke, or a first occur-
rence of hospitalization for heart failure; death from any cause; death
from cardiovascular causes; atrial fibrillation; the Minnesota Living
with Heart Failure score
 
22
 
; the pacemaker syndrome
 
23
 
 with a need
for permanent reprogramming to dual-chamber pacing; and health-
related quality of life. A clinical-events committee that was unaware
of the assigned pacing mode classified deaths according to cause and
adjudicated all suspected strokes and hospitalizations for heart
failure. An electrocardiographic core laboratory reviewed electro-
cardiograms and confirmed diagnoses of atrial fibrillation. Inves-
tigators at each site categorized patients as having chronic atrial
fibrillation if they had atrial fibrillation without intervening sinus
rhythm on more than one visit. The heart-failure score, which as-
signs points for symptoms and signs as well as intensification of
medical therapy for heart failure, correlates with exercise capacity
 
22
 
and mortality after myocardial infarction (unpublished data). Higher
points indicate more severe disease. The diagnosis of the pacemaker
syndrome required signs and symptoms of elevated right-sided or
left-sided filling pressures or hypotension with ventricular pacing.
 
13,15
 
Statistical Analysis
 
The study was designed to have over 90 percent power to detect
a 25 percent reduction in the rate of the primary end point and over
80 percent power to detect a 25 percent reduction in mortality
in the dual-chamber group. Unless otherwise specified, treatment
groups were compared on an intention-to-treat basis. All statistical
tests were two-tailed. Cumulative event rates were calculated by
the Kaplan–Meier method,
 
24
 
 and differences between the treatment
groups were assessed with the log-rank test.
 
25
 
 Relative risk was
expressed as a hazard ratio (with a 95 percent confidence interval).
 
26
 
As specified in the study protocol, supplemental analyses adjusted
for selected base-line characteristics with the use of the Cox pro-
portional-hazards model.
 
26
 
 An independent data and safety mon-
itoring board monitored interim analyses with two-sided, symmetric
O’Brien–Fleming
 
27
 
 boundaries generated with the Lan–DeMets
 
28
 
spending-function approach to group-sequential testing. The heart-
failure score, calculated as an average score per visit, was analyzed
with the use of the Wilcoxon rank-sum test.
Each of the SF-36 scale and summary scores, the time-tradeoff
utility scores, and the score on the Specific Activity Scale were com-
pared with the use of a repeated-measures analysis of variance. An
unstructured correlation matrix was used to adjust for dependence
across the five time points, and the model included covariates for
age group, sex, and base-line quality of life. Since there were no
significant interactions between time and the effect of treatment,
significance testing considered only the single-effect estimate across
all time points. Analyses are presented as the adjusted average change
from base line in each study group. For patients who crossed over
from single to dual pacing, health status at the time of the crossover
was carried forward; in a secondary analysis, actual health status,
which commonly was improved by crossing over, was assessed. The
principal investigators had full access to the data and independently
performed all data analyses.
 
RESULTS
 
Base-Line Characteristics
 
The median age of the 2010 patients was 74 years;
48 percent were women (Table 1). Hypertension was
reported by 62 percent, and diabetes by 22 percent. A
history of myocardial infarction was reported by 26
percent of patients, and a history of heart failure by 20
percent. Over 80 percent of patients were in New York
Heart Association class I or II at base line. Over 50
percent of patients had a history of supraventricular
tachycardia, generally atrial fibrillation or flutter that
had occurred within the past three weeks. The indica-
tion for pacemaker implantation was sinus-node dys-
function in all cases, but 21 percent of patients also
had atrioventricular block. A total of 1014 patients
were assigned to dual-chamber pacing, and 996 pa-
tients were assigned to ventricular pacing.
 
Primary End Point
 
The primary end point, death or nonfatal stroke,
occurred in 447 patients (22.2 percent). There were
no significant differences between patients receiving
dual-chamber pacing (21.5 percent) and those re-
ceiving ventricular pacing (23.0 percent, P=0.48)
(Fig. 1 and Table 2).
The New England Journal of Medicine 
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Death, Nonfatal Stroke, or Hospitalization for Heart Failure
 
Stroke occurred in 4.5 percent of the study popula-
tion, death from any cause in 20.1 percent, and the
composite end point — death, stroke, or hospitaliza-
tion for heart failure — in 28.8 percent. Death from
cardiovascular causes occurred in 8.9 percent. Unad-
justed analyses did not reveal any significant differences
between the treatment groups in the rate of any of the
end points (Fig. 1 and Table 2).
 
Atrial Fibrillation
 
Atrial fibrillation occurred in 24.2 percent of the
study population, including 4.8 percent in whom it
developed for the first time. The incidence of atrial
fibrillation after randomization was significantly lower
in the dual-chamber group (hazard ratio, 0.79; 95
percent confidence interval, 0.66 to 0.94; P=0.008)
(Fig. 1 and Table 2). Of 487 patients in whom atrial
fibrillation developed after randomization, 105 (21.6
percent) had chronic atrial fibrillation (15.2 percent of
patients with dual-chamber pacing, as compared with
26.7 percent of patients with ventricular pacing;
hazard ratio for chronic atrial fibrillation in the over-
all study population, 0.44; 95 percent confidence in-
terval, 0.29 to 0.67; P<0.001). Patients receiving
dual-chamber pacing who had no history of atrial fi-
brillation had a 50 percent lower incidence of atrial
fibrillation after randomization (hazard ratio as com-
pared with ventricular pacing, 0.50; 95 percent confi-
dence interval,  0.32 to 0.76; P=0.001), whereas pa-
tients receiving dual-chamber pacing who had a
history of atrial fibrillation had a smaller, nonsignifi-
cant 14 percent reduction (hazard ratio, 0.86; 95 per-
cent confidence interval, 0.70 to 1.04; P=0.12).
 
Heart Failure
 
Hospitalization for heart failure occurred in 10.3
percent of the patients receiving dual-chamber pac-
ing and 12.3 percent of the patients receiving ventric-
ular pacing (hazard ratio, 0.82; 95 percent confidence
interval, 0.63 to 1.06; P=0.13). Patients who did not
have a history of heart failure at the time of enrollment
accounted for 51 percent of hospitalizations for heart
failure, and the hazard ratios for the treatment groups
were similar in patients with a history of heart failure
(0.74; 95 percent confidence interval, 0.51 to 1.07)
and without such a history (0.79; 95 percent confi-
dence interval, 0.55 to 1.13). During follow-up, pa-
tients receiving dual-chamber pacing accumulated few-
er points per visit on the heart-failure score than did
patients receiving ventricular pacing (average points
per visit during follow-up: ventricular pacing, 1.75;
dual-chamber pacing, 1.49; P<0.001).
 
Adjusted Analyses
 
Multivariable analyses were performed to control
for slightly higher proportions of patients with a histo-
ry of myocardial infarction, diabetes, congestive heart
failure, and supraventricular tachycardia in the group
receiving dual-chamber pacing. Adjusted analyses had
minimal influence on the estimate of the effect of
treatment on the primary end point. However, the
adjusted hazard ratio was 0.73 (95 percent confidence
interval, 0.56 to 0.95; P=0.02) for hospitalization
for heart failure and 0.85 (95 percent confidence inter-
val, 0.72 to 1.00; P=0.05) for death, stroke, or hospi-
talization for heart failure (the combined clinical end
point).
 
Prespecified Subgroups
 
There were no statistically significant differences
in the risk of death, stroke, and hospitalization for
heart failure between the two treatment groups among
 
*P values for categorical variables present in less than 10 percent of patients
were calculated with Fisher’s exact test; for other categorical variables,
P values were calculated with the likelihood-ratio chi-square test. For con-
tinuous variables, P values were calculated with the Wilcoxon rank-sum test.
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Age (yr) 0.58
Median 74 74 
Interquartile range 68–80 67–80
 
no. (%)
 
Female sex 477 (48) 478 (47) 0.74
Nonwhite race 144 (14) 162 (16) 0.34
Hypertension 608 (61) 640 (63) 0.34
Hypercholesterolemia 340 (34) 376 (37) 0.17
Current smoker 85 (9) 84 (8) 0.87
Prior myocardial infarction 243 (24) 279 (28) 0.11
Prior heart failure 183 (18) 221 (22) 0.05
New York Heart Association 
class I or II heart failure
841 (84) 822 (81) 0.05
Cardiomyopathy 106 (11) 133 (13) 0.09
Prior stroke 108 (11) 116 (11) 0.67
Diabetes 204 (20) 246 (24) 0.04
Chronic pulmonary disease 109 (11) 109 (11) 0.89
Percutaneous transluminal 
coronary angioplasty
119 (12) 131 (13) 0.50
Coronary-artery bypass grafting 215 (22) 222 (22) 0.87
Other cardiac surgery 88 (9) 83 (8) 0.63
Implantation of cardioverter–
defibrillator
6 (1) 13 (1) 0.17
Any supraventricular tachycardia 514 (52) 545 (54) 0.34
Atrial fibrillation 440 (44) 477 (47) 0.20
Other atrial tachycardia 92 (9) 94 (9) 0.99
Any atrioventricular block 209 (21) 204 (20) 0.62
Complete heart block 52 (5) 39 (4) 0.16
Second-degree heart block 62 (6) 72 (7) 0.48
Prolonged atrioventricular interval 102 (10) 101 (10) 0.83
Other heart block 23 (2) 25 (2) 0.88
Vasovagal syndromes 33 (3) 28 (3) 0.52
Ventricular tachycardia or 
ventricular fibrillation
24 (2) 42 (4) 0.03
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patients over 75 years of age, women, nonwhite pa-
tients, or patients with a history of supraventricular
tachycardia (Fig. 2).
 
Quality of Life
 
At three months, both ventricular pacing and dual-
chamber pacing led to substantial improvement in
the SF-36 physical role (18 points for ventricular pac-
ing, about 1.3 times the effect of a history of angina
or heart failure in study patients), but a much smaller
1.9-point change in the SF-36 physical function
(only about 10 to 15 percent of the effect of a history
of angina or heart failure in study patients). Over a
period of four years, dual-chamber pacing provided
 
Figure 1.
 
 Rates of Clinical Events According to the Mode of Pacing.
An explanation of adjusted and unadjusted analyses is provided in the Methods section. Unadjusted P values were derived with
the log-rank test.
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significant improvements in health-related quality of
life, as compared with ventricular pacing, for six of
eight SF-36 subscales in the carry-forward analysis
(Table 3). Summary scores for both physical and men-
tal components also improved significantly. If health
status after crossover was included in the analysis,
there were no significant differences between the two
groups.
 
Pacemaker Syndrome
 
During the course of the trial, 374 patients receiv-
ing ventricular pacing (37.6 percent) had their pace-
makers reprogrammed to dual-chamber pacing; 61
of the patients were subsequently switched back to
the originally assigned mode. Thus, at the last follow-
up, 313 patients (31.4 percent) assigned to ventricular
pacing were receiving dual-chamber pacing. The pace-
 
*CI denotes confidence interval.
†Values have been adjusted for age, sex, history of stroke, history of supraventricular arrhythmia, history of heart failure, history of myocardial infarction,
history of ventricular tachycardia or ventricular fibrillation, and score on the Charlson comorbidity index.
‡The combined clinical end point included death from any cause, a first occurrence of nonfatal stroke, or a first hospitalization for heart failure.
 
T
 
ABLE
 
 2.
 
 C
 
LINICAL
 
 E
 
VENTS
 
 
 
AND CLINICAL END POINTS.*
EVENT OR END POINT
VENTRICULAR
PACING 
DUAL-CHAMBER
PACING
UNADJUSTED 
HAZARD 
RATIO
UNADJUSTED 
95% CI P VALUE
ADJUSTED 
HAZARD 
RATIO
ADJUSTED 
95% CI† P VALUE
percent
Death or stroke 23.0 21.5 0.93 0.78–1.13 0.48 0.91 0.75–1.10 0.32
Combined clinical end point‡ 29.9 27.6 0.90 0.77–1.06 0.23 0.85 0.72–1.00 0.05
Death 20.5 19.7 0.97 0.80–1.18 0.78 0.95 0.78–1.16 0.64
Stroke 4.9 4.0 0.82 0.54–1.25 0.36 0.81 0.54–1.23 0.33
Death from cardiovascular causes 9.2 8.5 0.93 0.69–1.24 0.61 0.87 0.65–1.18 0.37
Hospitalization for heart failure 12.3 10.3 0.82 0.63–1.06 0.13 0.73 0.56–0.95 0.02
Atrial fibrillation 27.1 21.4 0.79 0.66–0.94 0.008 0.77 0.64–0.92 0.004
Figure 2. Unadjusted Subgroup Comparisons According to the Mode of Pacing.
Shown are the unadjusted hazard ratios for the secondary composite end point (death, stroke, or hos-
pitalization for heart failure) for the patients assigned to dual-chamber pacing as compared with those
assigned to ventricular pacing. CI denotes confidence interval. 
CHARACTERISTIC
All patients
Sex 
    Female 
    Male
Age 
    »75 years 
    <75 years
Race 
    White 
    Nonwhite
History of supra- 
        ventricular 
        tachycardia
    Yes
    No 
    
  NO. OF 
PATIENTS
   2010
   0955 
   1055
   0987 
   1023
   1704 
   0306
         
        
   1059
   0951 
    
HAZARD RATIO (95% CI)
    0.90 (0.77–1.06)
    0.89 (0.71–1.13) 
    0.91 (0.73–1.15)
    0.97 (0.79–1.21) 
    0.83 (0.65–1.07)
    0.88 (0.73–1.05) 
    1.00 (0.68–1.46)
    0.92 (0.74–1.14)
    0.88 (0.69–1.13) 
    
0.5 2.01.0
Better Results with 
Dual-Chamber 
Pacing
Better Results
with Ventricular 
Pacing
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 14, 2015. For personal use only. No other uses without permission. 
 Copyright © 2002 Massachusetts Medical Society. All rights reserved. 
VENTRICULAR PACING VS. DUAL-CHAMBER PACING
N Engl J Med, Vol. 346, No. 24 · June 13, 2002 · www.nejm.org · 1859
*P
 v
al
ue
s 
(w
hi
ch
 a
re
 n
ot
 s
ho
w
n)
 f
or
 c
om
pa
ri
so
ns
 w
ith
 b
as
e 
lin
e 
w
er
e 
al
l l
es
s 
th
an
 0
.0
5 
ex
ce
pt
 f
or
 p
er
ce
pt
io
n 
of
 h
ea
lth
 a
nd
 s
co
re
 o
n 
th
e 
Sp
ec
ifi
c 
A
ct
iv
it
y 
Sc
al
e.
†A
ll 
ar
e 
SF
-3
6 
sc
al
es
 e
xc
ep
t 
fo
r 
th
e 
Sp
ec
ifi
c 
A
ct
iv
it
y 
Sc
al
e 
an
d 
th
e 
tim
e-
tr
ad
eo
ff
 u
til
it
y 
sc
al
e.
 F
or
 a
ll 
SF
-3
6 
sc
al
es
 a
nd
 c
om
po
ne
nt
 s
um
m
ar
ie
s, 
a 
po
si
tiv
e 
nu
m
be
r 
de
no
te
s 
im
pr
ov
ed
 q
ua
lit
y 
of
 li
fe
. 
Fo
r 
th
e
sc
or
e 
on
 t
he
 S
pe
ci
fic
 A
ct
iv
it
y 
Sc
al
e,
 a
 lo
w
er
 n
um
be
r 
de
no
te
s 
im
pr
ov
ed
 q
ua
lit
y 
of
 li
fe
. F
or
 t
im
e-
tr
ad
eo
ff
 u
til
it
y,
 a
 p
os
iti
ve
 n
um
be
r 
de
no
te
s 
im
pr
ov
em
en
t.
‡ 
T
he
 s
co
re
 r
ep
re
se
nt
s 
th
e 
di
ffe
re
nc
e 
be
tw
ee
n 
th
e 
gr
ou
p 
of
 p
at
ie
nt
s 
as
sig
ne
d 
to
 v
en
tr
ic
ul
ar
 p
ac
in
g 
an
d 
th
e 
gr
ou
p 
as
sig
ne
d 
to
 d
ua
l-
ch
am
be
r 
pa
ci
ng
, w
he
re
 a
 p
lu
s 
sig
n 
in
di
ca
te
s 
a 
be
tt
er
 r
es
ul
t 
in
 t
he
 g
ro
up
as
sig
ne
d 
to
 d
ua
l-
ch
am
be
r 
pa
ci
ng
. P
 v
al
ue
s 
ar
e 
fo
r 
th
e 
co
m
pa
ri
so
n 
be
tw
ee
n 
th
e 
tw
o 
gr
ou
ps
.
T
A
B
LE
 3
. C
H
A
N
G
E
S 
FR
O
M
 B
A
SE
 L
IN
E
 I
N
 Q
U
A
L
IT
Y 
O
F 
L
IF
E
 A
FT
E
R
 P
A
C
IN
G
.*
Q
U
A
LI
T
Y
-O
F-
LI
FE
 S
C
A
LE
†
B
A
S
E
 L
IN
E
3 
M
O
N
T
H
S
12
 M
O
N
T
H
S
24
 M
O
N
T
H
S
36
 M
O
N
T
H
S
48
 M
O
N
T
H
S
C
H
A
N
G
E
 F
R
O
M
 
B
A
S
E
 L
IN
E
 A
FT
E
R
48
 M
O
N
T
H
S
‡
V
E
N
T
R
IC
U
L
A
R
D
U
A
L
V
E
N
T
R
IC
U
L
A
R
D
U
A
L
V
E
N
T
R
IC
U
L
A
R
D
U
A
L
V
E
N
T
R
IC
U
L
A
R
D
U
A
L
V
E
N
T
R
IC
U
L
A
R
D
U
A
L
V
E
N
T
R
IC
U
L
A
R
D
U
A
L
SC
O
R
E
P 
V
A
L
U
E
Ph
ys
ic
al
 f
un
ct
io
n
58
.8
58
.9
+
1.
9
+
4.
3
+
0.
5
+
1.
8
–
1.
7
+
0.
7
–
2.
9
–
0.
7
–
3.
2
–
0.
1
+
1.
9
0.
04
Ph
ys
ic
al
 r
ol
e
35
.7
34
.6
+
17
.8
+
25
.5
+
21
.5
+
27
.7
+
17
.1
+
28
.4
+
17
.1
+
32
.7
+
18
.0
+
26
.7
+
8.
6
<
0.
01
So
ci
al
 f
un
ct
io
n
63
.5
62
.6
+
6.
3
+
9.
1
+
6.
7
+
9.
3
+
4.
3
+
6.
3
+
4.
3
+
7.
8
+
6.
4
+
9.
8
+
2.
5
<
0.
01
E
ne
rg
y
41
.9
42
.6
+
7.
1
+
11
.6
+
6.
3
+
9.
3
+
4.
0
+
7.
1
+
1.
7
+
8.
3
+
3.
6
+
5.
2
+
4.
1
<
0.
01
M
en
ta
l h
ea
lth
72
.0
72
.0
+
2.
2
+
2.
8
+
1.
7
+
3.
1
+
1.
6
+
3.
2
+
1.
6
+
5.
6
+
4.
7
+
4.
6
+
1.
2
0.
05
E
m
ot
io
na
l r
ol
e
74
.0
74
.0
+
5.
0
+
6.
9
+
4.
6
+
9.
1
+
4.
3
+
9.
2
+
4.
7
+
11
.4
+
4.
8
+
12
.3
+
3.
6
<
0.
01
Pa
in
67
.5
67
.0
+
4.
2
+
4.
4
+
3.
3
+
3.
7
+
0.
4
+
2.
4
+
3.
5
+
4.
6
+
6.
9
+
5.
1
+
0.
5
0.
57
H
ea
lth
 p
er
ce
pt
io
n
60
.0
60
.2
0.
0
+
1.
9
–
0.
8
–
0.
2
–
3.
4
–
3.
1
–
3.
4
–
3.
1
–
3.
5
–
2.
5
+
1.
1
0.
09
M
en
ta
l-
co
m
po
ne
nt
 s
um
m
ar
y
48
.4
48
.4
+
1.
8
+
2.
6
+
1.
5
+
2.
8
+
1.
4
+
2.
3
+
1.
4
+
3.
6
+
2.
4
+
3.
5
+
1.
1
<
0.
01
Ph
ys
ic
al
-c
om
po
ne
nt
 s
um
m
ar
y
38
.5
38
.4
+
2.
2
+
3.
7
+
2.
1
+
2.
7
+
0.
6
+
2.
0
+
0.
7
+
2.
3
+
1.
0
+
2.
2
+
1.
2
<
0.
01
Sp
ec
ifi
c 
A
ct
iv
it
y 
Sc
al
e
2.
01
1.
97
–
0.
04
–
0.
06
0.
00
+
0.
02
+
0.
03
+
0.
05
+
0.
04
+
0.
11
+
0.
16
+
0.
13
+
0.
00
2
0.
94
T
im
e-
tr
ad
eo
ff 
ut
ili
ty
 (
%
)
73
72
+
7
+
8
+
5
+
8
+
4
+
7
+
4
+
8
+
6
+
6
+
2
0.
06
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 14, 2015. For personal use only. No other uses without permission. 
 Copyright © 2002 Massachusetts Medical Society. All rights reserved. 
1860 · N Engl J Med, Vol. 346, No. 24 · June 13, 2002 · www.nejm.org
The New England Journal  of  Medicine
maker syndrome as strictly defined by the protocol
was present in 113 of these patients, whereas an addi-
tional 69 had symptoms of severe pacemaker syn-
drome but did not fully meet the strict definition.
Consequently, clinical pacemaker syndrome was the
principal reason for crossover in 18.3 percent of pa-
tients assigned to ventricular pacing and in 48.9 per-
cent of all patients who crossed over. Most crossovers
due to the pacemaker syndrome occurred early (69
percent by 3 months and 73 percent by 6 months;
median time to crossover, 58 days). Other reasons for
crossover are listed in Table 4.
Complications
The rate of complications within 30 days after pace-
maker implantation was 4.8 percent. The most fre-
quent complications were dislodgement or failure of
the atrial lead in 1.8 percent, pneumothorax in 1.5
percent, and complications associated with the ventric-
ular lead in 1.1 percent. There were no instances of
death as a complication of implantation of a perma-
nent pacemaker.
DISCUSSION
In 2000, over 225,000 pacemakers were implanted
in the United States, and over 600,000 were implant-
ed worldwide. Historically, sinus-node dysfunction,
a disorder of unknown cause, represents the diagnosis
leading to implantation in about one half of all pace-
maker recipients in the United States.10 To date, clinical
recommendations and guidelines regarding the selec-
tion of pacing systems have been based on small clini-
cal studies and retrospective analyses of existing data
bases.29
When viewed in aggregate, the first randomized
trials comparing ventricular with dual-chamber pac-
ing11-14 suggested that dual-chamber pacing reduces
the rates of death, stroke, and heart failure, particularly
among patients with sinus-node dysfunction. These
small trials led to the expectation that larger trials
would confirm the superiority of dual-chamber pacing
for sinus-node dysfunction.
The Canadian Trial of Physiologic Pacing (CTOPP)8
compared physiologic (i.e., atrial or dual-chamber)
pacing with ventricular pacing in 2568 patients and
reported no differences in the rates of death, stroke,
or hospitalizations for heart failure. CTOPP included
1077 patients with sinus-node dysfunction and thus
did not have sufficient statistical power to exclude a
moderate benefit of physiologic pacing. In the present
trial in 2010 patients, we also found no statistically
significant differences when comparing dual-chamber
with ventricular pacing in terms of death from any
cause, death from cardiovascular causes, or stroke.
The loss of atrioventricular synchrony with ven-
tricular pacing is associated with enlargement of the
left atrium,30 and retrospective studies noted a marked
reduction in atrial fibrillation31 with dual-chamber
pacing. A more moderate reduction, principally in pa-
tients with sinus-node disease, was found in two small
prospective trials12,13 and confirmed by CTOPP. In
contrast to CTOPP, 21 percent of whose patients had
a history of supraventricular arrhythmia, the prevalence
of prior supraventricular tachycardia in our trial was
over 50 percent, and we found a 56 percent reduction
in the subsequent development of chronic atrial fibril-
lation with dual-chamber pacing than with ventricular
pacing.
The preservation of atrioventricular synchrony has
been thought to be central to the maintenance of op-
timal cardiac performance.5-7 Signs and symptoms of
heart failure, as assessed by the heart-failure score,22
were less severe with dual-chamber pacing than with
ventricular pacing. Unadjusted comparisons of hos-
pitalizations for heart failure reflected an insignificant
18 percent reduction in risk, whereas multivariable
analyses that adjusted for base-line imbalances revealed
a marginally significant reduction in hospitalizations
for heart failure with dual-chamber pacing.
A high incidence of the pacemaker syndrome,
which is thought to be due to loss of atrioventricular
synchrony, was observed in the group receiving ven-
tricular pacing.32 In observational studies, the inci-
dence of the pacemaker syndrome has been reported
to be as high as 83 percent.33 In the Pacemaker Selec-
tion in the Elderly (PASE) trial, the pacemaker syn-
drome occurred in 26 percent of patients during an
average follow-up of 18 months.13 In our trial, 16.5
percent of the patients receiving ventricular pacing
*Chronotropic incompetence was defined as the failure to
increase heart rate with exercise.
TABLE 4. REASONS FOR PERMANENT CROSSOVERS 
FROM VENTRICULAR TO DUAL-CHAMBER PACING.
REASON NO. OF PATIENTS
Severe pacemaker syndrome requiring 
permanent reprogramming
182
Refractory heart failure 39
Chronotropic incompetence* 27
Physician’s preference or refusal 22
Supraventricular arrhythmias 19
Possible pacemaker syndrome 8
Patient’s refusal 4
Rate response causing angina 2
Vasovagal syndrome 2
Physician’s error or programming error 1
Recurrent syncope 1
Unknown 6
Total 313
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 14, 2015. For personal use only. No other uses without permission. 
 Copyright © 2002 Massachusetts Medical Society. All rights reserved. 
VENTRICULAR PACING VS. DUAL-CHAMBER PACING
N Engl J Med, Vol. 346, No. 24 · June 13, 2002 · www.nejm.org · 1861
crossed over to dual-chamber pacing because of the
pacemaker syndrome. In both the PASE trial and our
study, about 75 percent of crossovers occurred within
six months.
The high incidence of the pacemaker syndrome
reported here is in sharp contrast to the low incidence
(1.7 percent) reported by Andersen et al.11,12 and the
2.7 percent rate at three years reported in CTOPP.8
In our study and the PASE trial,13,31 only reprogram-
ming was required to change from ventricular to phys-
iologic pacing, whereas reoperation was necessary in
the other two studies. Nonetheless, we cannot exclude
the possibility that there are different clinical thresh-
olds for the diagnosis of such a subjective condition
in different countries.
The quality-of-life benefits of dual-chamber pacing
over ventricular pacing were generally small in com-
parison with the differences based on the presence
of angina or heart failure. Although physical role im-
proved by an amount equivalent to about 60 percent
of the improvement associated with a change of one
class on the Specific Activity Scale, the changes were
much smaller for physical function and perception of
health. These data suggest that dual-chamber pacing
has incremental benefits in terms of the ability to per-
form physical tasks at the margin of a person’s own
capacity but does not have dramatic incremental ben-
efits over ventricular pacing in terms of the number
of blocks walked or stairs climbed. In addition, the
incremental benefits of dual-chamber pacing were,
in part, offset by age-related declines in function over
the course of the study.
Limitations in the design of the study may have
affected our results. We randomly assigned program-
ming, not the type of pacemaker. Since mode changes
are easier with this design, we may have overestimated
the true incidence of the pacemaker syndrome and
reduced the number of clinical events in the ventric-
ular-pacing group. Dual-chamber pacing, by necessity,
led to atrial synchronous ventricular pacing in many
patients. There is increasing recognition that a ven-
tricular-paced beat, with a wide QRS interval and left
bundle-branch block morphology, may be hemody-
namically disadvantageous and may even blunt the
benefits of atrial pacing. Finally, given the study de-
sign, it is impossible to determine whether atrial-
based pacing prevents atrial fibrillation or whether
ventricular pacing is arrhythmogenic and thus causes
atrial fibrillation.
We conclude that for patients with sinus-node
dysfunction, dual-chamber pacing, as compared with
single-chamber ventricular pacing, did not improve
the rate of our primary end point of stroke-free sur-
vival. However, when compared with ventricular pac-
ing, dual-chamber pacing reduces newly diagnosed
and chronic atrial fibrillation, reduces signs and symp-
toms of heart failure, and slightly improves the quality
of life.
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ease Specialists, Atlanta: T. Deering; Christ Hospital, Cincinnati: R.
Henthorn, S. Behrens, and T. Waller; Christiana Hospital, Newark, N.J.:
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N.J.: C. Dennis and R. Corbisiero; Duke University Medical Center,
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